Condition
Hemodialysis Access
Total Trials
6
Recruiting
2
Active
3
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 1 (1)
Trial Status
Completed3
Recruiting2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04907240Active Not Recruiting
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
NCT07153939Not ApplicableRecruiting
Pivotal Study of the Velocity™ pAVF System
NCT07372027Not ApplicableRecruitingPrimary
Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care
NCT06236867Not ApplicableCompletedPrimary
Cannulation-Related Pain in Dialysis Patients With Arteriovenous Fistula
NCT02376361Not ApplicableCompletedPrimary
Hemodialysis Access Surveillance Evaluation Study
NCT00479180Phase 1CompletedPrimary
Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use
Showing all 6 trials